|April 16, 2021
FDA Update & Statement on Johnson & Johnson COVID-19 Vaccine Pause Recommendation
On Tuesday, the FDA and Centers for Disease Control and Prevention (CDC) issued a Statement regarding the Janssen (Johnson & Johnson) COVID-19 Vaccine. Out of an abundance of caution, the FDA and CDC recommended a pause in the use of this vaccine while we review the data from six reported cases in the U.S. of a rare and severe type of blood clot in people who received the vaccine. This pause was recommended, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot.
The FDA added three questions about the recommended pause in the use of this vaccine to the Janssen COVID-19 Frequently Asked Questions webpage and provided additional information and answered questions, Tuesday during an online media briefing. A recording of the call can be found on YouTube by clicking here.
American Medical Association President, Susan R. Bailey, MD, hosted a conversation with Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA) as part of its ongoing webinar series for physicians on COVID-19 vaccines. The most recent webinar focused on the Johnson & Johnson (Janssen) vaccine. You can view the webinar at this link.< Previous Article | Next Article >
[ return to top ]
ensure delivery of Maine Medicine Weekly Update,
please add 'firstname.lastname@example.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm
For more information or to contact us directly, please visit www.mainemed.com | ©